ANA KAROLINA BARRETO BERSELLI MARINHO

(Fonte: Lattes)
Índice h a partir de 2011
7
Lattes
ResearcherID
ORCID
Projetos de Pesquisa
Unidades Organizacionais
Instituto Central, Hospital das Clínicas, Faculdade de Medicina - Médico
LIM/60 - Laboratório de Imunologia Clínica e Alergia, Hospital das Clínicas, Faculdade de Medicina

Filtros

Limpar filtros

Configurações

Categoria: review ×

Resultados de Busca

Agora exibindo 1 - 2 de 2
  • article 2 Citação(ões) na Scopus
    Vaccination in children with immune-mediated disorders
    (2023) MARINHO, Ana Karolina Barreto Berselli
    Objective: To present an updated review of recommendations for the vaccination of children with immune-mediated diseases, with an emphasis on rheumatic and inflammatory diseases.Source of data: Studies published in the PubMed and Scielo databases between 2002 and 2022, Guidelines of Brazilian Scientific Societies, Manuals and Technical Notes of the Ministry of Health of Brazil, on current immunization schedules for special populations. Data synthesis: Immunosuppressive drugs and biological agents reduce the immunogenicity of vaccines and favor susceptibility to infections. The safety and efficacy of immunogens are impor-tant points for vaccination in children with immune-mediated diseases. The safety threshold of a vaccine applied to immunocompromised individuals can be reduced when compared to healthy individuals. Very often, the recommendations for the immunization of children with immune -mediated diseases follow the recommendations for immunocompromised patients. Vaccination against COVID-19, on the other hand, should ideally occur when the disease is stabilized and in the absence of a low degree of immunosuppression. The patients should be informed about the possibility that the immunization may fail during treatment with immunosuppressants. Specific vaccination schedules should be considered to ensure better protection.Conclusions: Recent studies have allowed updating the recommendations on the safety and immu-nogenicity of vaccination in children with immune-mediated diseases, especially for live attenu-ated vaccines. There is a scarcity of data on the safety and efficacy of COVID-19 vaccines in patients, particularly pediatric patients, with rheumatic diseases. The completion of ongoing stud-ies is expected to help guide recommendations on COVID-19 vaccines in this group of patients.(c) 2022 Sociedade Brasileira de Pediatria.
  • article 2 Citação(ões) na Scopus
    COVID-19 and isolation: Risks and implications in the scenario of new variants
    (2022) DIAS, Viviane Maria de Carvalho Hessel; OLIVEIRA, Alexandre Ferreira; MARINHO, Ana Karolina Barreto Berselli; FERREIRA, Carlos Eduardo dos Santos; DOMINGUES, Carlos Eduardo Ferreira; FORTALEZA, Carlos Magno Castelo Branco; VIDAL, Claudia Fernanda de Lacerda; CARRILHO, Claudia Maria Dantas de Maio; PINHEIRO, Debora Otero Britto Passos; ASSIS, Denise Brandao de; MEDEIROS, Eduardo Alexandrino; MOREJON, Karen Mirna Loro; WEISSMANN, Leonardo; MICHELIN, Lessandra; CARNEIRO, Marcelo; NOGUEIRA, Maria Dolores Santos da Purificacao; OLIVEIRA, Priscila Rosalba Domingos de; BURALLI, Rafael Junqueira; STUCCHI, Raquel Silveira Bello; LINS, Rodrigo Schrage; COSTA, Silvia Figueiredo; CHEBABO, Alberto
    With the emergence of new variants of SARS-CoV-2, questions about transmissibility, vac-cine efficacy, and impact on mortality are important to support decision-making in public health measures. Modifications related to transmissibility combined with the fact that much of the population has already been partially exposed to infection and/or vaccination, have stimulated recommendations to reduce the isolation period for COVID-19. However, these new guidelines have raised questions about their effectiveness in reducing contami-nation and minimizing impact in work environments. Therefore, a collaborative task force was developed to review the subject in a non-systematic manner, answering questions about SARS-CoV-2 variants, COVID-19 vaccines, isolation/quarantine periods, testing to end the isolation period, and the use of masks as mitigation procedures. Overall, COVID-19 vaccines are effective in preventing severe illness and death but are less effective in pre-venting infection in the case of the Omicron variant. Any strategy that is adopted to reduce the isolation period should take into consideration the epidemiological situation of the geo-graphical region, individual clinical characteristics, and mask for source control. The use of tests for isolation withdrawal should be evaluated with caution, due to results depending on various conditions and may not be reliable.(c) 2022 Sociedade Brasileira de Infectologia.